Table 4.
Number of ovarian follicles and surface of dominant follicle, assessed by transvaginal ultrasound
| Placebo (n = 27) | Fezolinetant 60 mg (n = 23) | Fezolinetant 180 mg (n = 23) | |
|---|---|---|---|
| No. of follicles, left ovary | |||
| Baseline | 16.9 (11.2) | 14.4 (6.9) | 17.8 (7.8) |
| Wk 6 change | −2.0 (8.7) | 0.1 (7.3) | −0.4 (11.2) |
| Wk 12 change | −0.7 (10.1) | −1.8 (8.2) | 3.7 (13.1) |
| No. of follicles, right ovary | |||
| Baseline | 19.1 (12.8) | 13.9 (7.0) | 18.7 (12.8) |
| Wk 6 change | −2.1 (11.4) | −1.0 (4.2) | −2.1 (8.6) |
| Wk 12 change | −1.2 (9.8) | 0.6 (6.6) | 3.1 (12.4) |
| Surface of dominant follicle, mm 3 | |||
| Baseline | 102.8 (103.6) | 220.0 (354.4) | 140.4 (255.5) |
| Wk 6 change | −54.7 (113.9) | −145.8 (349.9) | −19.8 (151.3) |
| Wk 12 change | −24.0 (153.6) | −99.2 (311.9) | 15.6 (43.7) |
All results are reported as mean (SD).